Precision Dosing Leader Abreos Biosciences Announces New Investment Round

SAN DIEGO--(BUSINESS WIRE)--Abreos Biosciences, a San Diego-based biotech company and a leader in the precision dosing of biological therapeutics, is pleased to announce that it has completed a new investment round. The funding came from existing investors as well as new investor TLP Investment Partners LLC and its affiliates.

The unique Abreos Veritope^TM technology platform allows for the selective monitoring of therapeutic antibody drugs, whether brand name or biosimilars. By monitoring the levels of these therapies, clinicians can optimize therapeutic dose and timing to help achieve optimal response to these expensive therapies.

“Biologics are among the most powerful therapeutics available for many serious diseases, yet many patients are under- or over-dosed due to the lack of simple monitoring tests that can tell how much drug a patient has in their blood. We are hoping to make personalized, precision dosing a reality for these patients,” said Bradley Messmer, Ph.D., CEO and founder of Abreos.

Abreos believes they can positively impact patient care while moderating costs through effective precision dosing. To date, tests for therapies in four major clinical areas, including autoimmune disease, oncology, neurology, and cardiology, have been developed by the company. These assays include those for rituximab, vendolizumab, adalimumab, pembrolizumab, obinutuzumab, trastuzumab, ipilumumab, natalizumab, and ocrelizumab.

About Abreos Biosciences

Abreos Biosciences was founded in 2013 by Dr. Bradley Messmer, the CEO, and is focused on developing technologies for monitoring antibody therapies in blood as well as point-of-care devices for clinical testing.